From: Nucleic acid direct delivery to fibroblasts: a review of nucleofection and applications
Cell type | Species | Passage | Cell confluence | Procedure | Cell viability | Transfection efficiency | Reference |
---|---|---|---|---|---|---|---|
Dermal fibroblasts | Rat | 2 | 80%-90% | U-30 | > 95.00% | ·51.50% ± 7.90% (Standard method) ·80.50% ± 5.00% (Modified method: DMEM + 10% FCS) | [11] |
Dermal fibroblasts | Rat | ≤ 3 | 80%-90% | U-30 | / | ·68.34% ± 10.32% (Standard method) ·85.35% ± 11.56% (Modified method: DMEM + 10% FCS) | [13] |
Dermal fibroblasts | Human | ≤ 3 | 80%-90% | U-24 | / | ·83.88% ± 9.67% (Standard method) ·57.88% ± 3.45% (Modified method: DMEM + 10% FCS) ·79.21% ± 1.62% (Modified method: ITS supplement) | [13] |
Dermal fibroblasts | Human | / | 80%-90% | U-20 | 80.00%- 90.00% | 40.00%-50.00% | [14] |
Dermal fibroblasts | Pig | 3–4 | / | V-13 | / | 60.10% | [19] |
Dermal fibroblasts | Rat | 2–4 | / | U-23 | 91.10% | 72.50% | [20] |
Dermal fibroblasts | Human | / | / | U-23 | 37.00% | 10.00% | [23] |
Dermal fibroblasts | Human | 1–5 | / | U-30 T-018 | > 68.70% | 34.60% | [28] |
Dermal fibroblasts | Pig | / | 90% | U-23 V-13 | 87.90% ± 7.40% (U23)/ 85.40% ± 7.50% (V13) | ·80.80% ± 6.20% (U23) ·86.00% ± 2.50% (V13) | [30] |
Sciatic nerve fibroblasts | Rat | / | 80% | T-16 | / | 80.00% | [31] |
Dermal fibroblasts | Rat | / | / | U-23 P-22 | / | ·57.33% (U-23) ·57.00% (P-22) | [33] |
Embryonic fibroblasts | Zebrafish | / | / | O-20 | 30.00%- 35.00% | 35.00%-43.00% | [35] |
Fetal fibroblast | Buffalo of Murrah breed | / | 70%-80% | EN-150 | 70.00%- 80.00% | 73.60% ± 1.36% | [36] |
Fetal fibroblast | Buffalo of Murrah breed | 2–3 | 70%-80% | EN-150 | 53.80% ± 4.20% | 73.50% ± 1.40% | [41] |
Embryo fibroblasts | Pig | 16 | / | U-20 | 95.00% | 90.00% | [46] |
Embryonic ear fibroblasts | Rabbit | / | / | U-23 | / | 38.00% | [46] |
Embryonic fibroblasts | Pig | 3–7 | / | U-23 | 57.80% | 79.00% ± 0.80% | [48] |
Kidney fibroblasts | Pig | / | / | T-007 | / | 65.00%-70.00% | [49] |